Based on the DiaMedica Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for DiaMedica Therapeutics Inc is USD 8.75 over the next 12 months. DiaMedica Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of DiaMedica Therapeutics Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, DiaMedica Therapeutics Inc’s stock price was USD 3.70. DiaMedica Therapeutics Inc’s stock price has changed by -6.57% over the past week, -35.88% over the past month and +36.53% over the last year.
No recent analyst target price found for DiaMedica Therapeutics Inc
No recent average analyst rating found for DiaMedica Therapeutics Inc
Company Overview DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Read Less
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kal...Read More
Frequently Asked Questions About DiaMedica Therapeutics Inc (DMAC) Stock
Based on ratings from 2 analysts DiaMedica Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on DMAC's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for DMAC is USD 8.75 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on DMAC's stock to indicate if its overvalued.
The last closing price of DMAC's stock was USD 3.70.
The most recent market capitalization for DMAC is USD 0.25B.
Based on targets from 2 analysts, the average taret price for DMAC is projected at USD 8.75 over the next 12 months.
This means that DMAC's stock price may go up by +136.49% over the next 12 months.
We can't find any ETFs which contains DiaMedica Therapeutics Inc's stock.
As per our most recent records DiaMedica Therapeutics Inc has 18 Employees.
DiaMedica Therapeutics Inc's registered address is 301 Carlson Parkway, Minneapolis, MN, United States, 55305.
You can get more information about it from DiaMedica Therapeutics Inc's website at https://www.diamedica.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About DiaMedica Therapeutics Inc (DMAC) Stock
Based on ratings from 2 analysts DiaMedica Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on DMAC's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for DMAC is USD 8.75 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on DMAC's stock to indicate if its overvalued.
The last closing price of DMAC's stock was USD 3.70.
The most recent market capitalization for DMAC is USD 0.25B.
Based on targets from 2 analysts, the average taret price for DMAC is projected at USD 8.75 over the next 12 months.
This means that DMAC's stock price may go up by +136.49% over the next 12 months.
We can't find any ETFs which contains DiaMedica Therapeutics Inc's stock.
As per our most recent records DiaMedica Therapeutics Inc has 18 Employees.
DiaMedica Therapeutics Inc's registered address is 301 Carlson Parkway, Minneapolis, MN, United States, 55305.
You can get more information about it from DiaMedica Therapeutics Inc's website at https://www.diamedica.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DMAC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
